O&G SAQs · Antenatal care — maternal immunisation
Vaccination in pregnancy — structured SAQ (15 marks)
FRANZCOG-format structured SAQ on vaccination in pregnancy: the four recommended vaccines with timing, transplacental IgG transfer physiology, the contraindicated live vaccines, and the management of the rubella-seronegative woman. Per-sub-part marking rubric included.
On this page
Study tools
Target exams
How this SAQ is marked
Twelve SAQs, 180 marks, two 2-hour papers — roughly 15 marks and 20 minutes each. Marks come from specifics: the named vaccines, their timing, the contraindicated live vaccines, and the mechanism. Write in short labelled points, not prose paragraphs. Answer the sub-part you are asked. [4]
Reveal model answer and mark schemeShowHide
(a) The four routinely recommended vaccines (5 marks)
One mark each for the first four (vaccine + timing + every-pregnancy), one mark for the overall principle. [4]
- Influenza (inactivated): any stage of each pregnancy, seasonal. Repeated every pregnancy.[1]
- Pertussis (dTpa): 20 to 32 weeks gestation (ANZ/ATAGI). Repeated every pregnancy.[2]
- RSV (Abrysvo, bivalent prefusion F): from 28 weeks gestation (ANZ), single dose, seasonal. Each pregnancy (where in season).[3]
- COVID-19: per current ATAGI/ACOG guidance. Recommended in pregnancy.[5]
- Principle: pertussis and RSV are given each pregnancy because antibody wanes between pregnancies and each infant needs a fresh antibody load transferred close to birth.[4]
(b) Mechanism and timing rationale (3 marks)
One mark for the dual mechanism, one for IgG transfer physiology, one for the timing rationale. [4]
- Dual mechanism: maternal vaccination protects the mother directly (active immunity) and the infant via passive transfer of maternal antibody.
- IgG transfer: maternal IgG crosses the placenta via the neonatal Fc receptor (FcRn); transfer is minimal early and accelerates sharply in the third trimester, so a term infant is born with antibody concentrations that often exceed the mother's.
- Timing rationale: pertussis (20 to 32 weeks) and RSV (28 to 36 weeks) are timed for the late second to third trimester so there is enough time for a robust maternal antibody response and maximal transfer before birth. Vaccinate too early and antibody wanes before peak transfer; too late and the infant is born before transfer is complete.[4]
(c) Contraindicated vaccines and why (3 marks)
One mark for naming them, one for the type, one for the rationale. [4]
- Live-attenuated vaccines contraindicated in pregnancy: MMR, varicella, BCG, live-attenuated influenza (LAIV), and yellow fever (unless risk unavoidable).
- These are live-attenuated vaccines — the organism replicates.
- Rationale: theoretical risk of fetal infection from the replicating organism. Documented harm is rare, but the precaution stands. If a live vaccine is given inadvertently, reassure and document — termination is not recommended for the vaccine alone.[4]
(d) Rubella-seronegative management (4 marks)
One mark for NOT giving MMR in pregnancy; one for the postpartum plan; one for breastfeeding/avoidance counselling; one for documenting and the rationale. [4]
- Do NOT administer MMR during pregnancy — it is live and contraindicated. (The reflex error is to give it; do not.)
- Defer MMR to the postpartum period — administer it before discharge from hospital.[4]
- Counsel: MMR is safe in breastfeeding; advise the woman to avoid pregnancy for one month after the dose.
- Document the seronegative status and the postpartum plan. Rationale: primary rubella infection in early pregnancy causes congenital rubella syndrome, so immunity matters and the postpartum catch-up is essential.[4]
References5ShowHide
- [1]Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants N Engl J Med, 2008.PMID 18799552
- [2]Dabrera G, Amirthalingam G, Andrews N, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013 Clin Infect Dis, 2015.PMID 25332078
- [3]Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants N Engl J Med, 2023.PMID 37018474
- [4]American College of Obstetricians and Gynecologists ACOG Committee Opinion No. 741: Maternal Immunization Obstet Gynecol, 2018.PMID 29794683
- [5]Morgan JA, Biggio JR Jr, Martin JK, et al. Pregnancy Outcomes in Patients After Completion of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccination Obstet Gynecol, 2023.PMID 36735413